Polarean Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Polarean's estimated annual revenue is currently $9.5M per year.(i)
  • Polarean's estimated revenue per employee is $251,000

Employee Data

  • Polarean has 38 Employees.(i)
  • Polarean grew their employee count by 9% last year.

Polarean's People

NameTitleEmail/Phone
1
Founder & CTOReveal Email/Phone
2
CEOReveal Email/Phone
3
CEOReveal Email/Phone
4
VP Technology & ApplicationsReveal Email/Phone
5
VP OperationsReveal Email/Phone
6
ControllerReveal Email/Phone
7
VP, Technology and ApplicationsReveal Email/Phone
8
Chairman / Director (previously CEO, COO)Reveal Email/Phone
9
Area DirectorReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M393%N/AN/A
#2
$15.1M607%N/AN/A
#3
$6M240%N/AN/A
#4
$24.8M99-12%N/AN/A
#5
$19.3M778%N/AN/A
#6
$28.1M11220%N/AN/A
#7
$3.8M15-46%N/AN/A
#8
$19.3M774%N/AN/A
#9
$45.4M1814%N/AN/A
#10
$6.8M27N/AN/AN/A
Add Company

What Is Polarean?

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs. The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

keywords:N/A

N/A

Total Funding

38

Number of Employees

$9.5M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Polarean News

2022-04-19 - Polarean Imaging secures new system order

Polarean, a medical imaging technology company with an investigational drug?device combination product using hyperpolarised 129 Xenon gas to...

2022-04-17 - Polarean Imaging says US regulator accepts updated submission

Polarean Imaging says US regulator accepts updated submission. The Food & Drug Administration set a user fee goal date, effectively a deadline...

2022-03-22 - Polarean Imaging upbeat as it resubmits new drug application to US FDA

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said it has resubmitted its new drug application (NDA) for a drug device that potentially offers a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.9M42-5%N/A
#2
$5.2M452%N/A
#3
$11.9M536%N/A
#4
$9.3M607%N/A
#5
$18M627%N/A